Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00312780 · ClinicalTrials.gov registry record · Phase 2
Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy
A Phase 2 study, sponsored by Symphony Evolution.
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
NCT00312780 is a Phase 2 study that has completed, run by Symphony Evolution. The registered enrollment target is 125 participants.
The verdict
NCT00312780, a Phase 2 study, has completed, sponsored by Symphony Evolution.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
Study Summary
This clinical study is being conducted at multiple sites to determine the activity, safety and tolerability of XL784 when given daily to patients with albuminuria due to diabetic nephropathy. XL784 is a small molecule reno-protective metalloproteinase inhibitor, inhibiting both ADAMs (including ADAM10, a target of significant interest because of its important role in blood vessel formation and cell proliferation, and ADAM17/TACE, activation of which has been associated with renal deterioration) and MMPs (including MMP-2 and MMP-9). XL784 was specifically optimized to be MMP-1 sparing, which may be clinically significant because inhibition of MMP-1 has been hypothesized to be associated with musculoskeletal toxicity.
Interventions
- DRUG XL784
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2006-03 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00312780
The ClinicalTrials.gov registry entry for NCT00312780 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Symphony Evolution, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XL784 is the first listed.
NCT00312780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00312780 about?
NCT00312780 is a clinical study titled "Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy". This clinical study is being conducted at multiple sites to determine the activity, safety and tolerability of XL784 when given daily to patients with albuminuria due to diabetic nephropathy. XL784 is a small molecule reno-protective metalloproteinase inhibitor, inhibiting both ADAMs (including ADAM...
What is the current status of trial NCT00312780?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2006-03. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00312780?
The interventions under investigation include: XL784 (DRUG).
Who is sponsoring clinical trial NCT00312780?
This trial is sponsored by Symphony Evolution, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.